Late Treatment With Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation

MLA

Brook, Matthew O., et al. “Late Treatment With Autologous Expanded Regulatory T-Cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation.” Transplantation, vol. 108, no. 11, Nov. 2024, pp. 2278–86. EBSCOhost, https://doi.org/10.1097/TP.0000000000005065.

APA

Brook, M. O., Hennessy, C., Hester, J., Hammad, S., Alzhrani, A., Rombach, I., Dutton, S., Lombardi, G., Wood, K. J., Friend, P., Harden, P. N., & Issa, F. (2024). Late Treatment With Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation. Transplantation, 108(11), 2278–2286. https://doi.org/10.1097/TP.0000000000005065

Chicago

Brook, Matthew O., Conor Hennessy, Joanna Hester, Salim Hammad, Alaa Alzhrani, Ines Rombach, Susan Dutton, et al. 2024. “Late Treatment With Autologous Expanded Regulatory T-Cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation.” Transplantation 108 (11): 2278–86. doi:10.1097/TP.0000000000005065.